Talk:Certolizumab pegol

This is the talk page for discussing improvements to the Certolizumab pegol article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Certolizumab pegol.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Info on Discovery, Patents, etc.

Would anyone have info on the discovery (who, where, when) of this molecule, as well as what company currently owns its patent? If you have this info, would you please add it to the article so that the reader can trace its history. Thank you. —Preceding unsigned comment added by Tell someone (talk • contribs) 15:51, 25 January 2009 (UTC)[reply]

Lack of quality regarding trial evidence

The information regarding trial evidence in Crohn's disease is out of date.

Schreiber S, Lawrance IC, Thomsen OO, Hanauer SB, Bloomfield R, Sandborn WJ. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Alimentary pharmacology & therapeutics 2011;33:185-93.

Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S, Investigators PS. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine 2007;357:228-38.

Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, Investigators PS. Maintenance therapy with certolizumab pegol for Crohn's disease.[Erratum appears in N Engl J Med. 2007 Sep 27;357(13):1357]. New England Journal of Medicine 2007;357:239-50. —Preceding unsigned comment added by 115.70.137.40 (talk) 07:43, 26 March 2011 (UTC)[reply]

It is incorrect to call Cimzia a monoclonal antibody

Cimzia (CDP870 development name) is not a monoclonal antibody but rather a Fab fragment of an antibody manufactured in a recombinant microbial culture. — Preceding unsigned comment added by 195.243.132.34 (talk) 07:11, 3 February 2016 (UTC)[reply]

External links modified

Hello fellow Wikipedians,

I have just modified one external link on Certolizumab pegol. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:

Added archive https://archive.is/20131001130038/http://www.ucb.presscentre.com/News/Cimzia-certolizumab-pegol-approved-by-the-U-S-FDA-for-treatment-of-adult-patients-with-active-ps-45c.aspx to http://www.ucb.presscentre.com/News/Cimzia-certolizumab-pegol-approved-by-the-U-S-FDA-for-treatment-of-adult-patients-with-active-ps-45c.aspx

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}} (last update: 5 June 2024).

If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
If you found an error with any archives or the URLs themselves, you can fix them with this tool.

Cheers.—InternetArchiveBot (Report bug) 08:19, 2 August 2017 (UTC)[reply]